Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer - Matthew D. Galsky; Begoña P. Valderrama; Marco Maruzzo; Albert Font; Tudor Ciuleanu; Jonathan Chatzkel; Takuya Koie; Christopher J. Hoimes; Javier Puente; Yousef Zakharia; Eli Rosenbaum; Katharina Boehm; et al. (New England Journal of Medicine, 2026)